ストックスクリーナーアプリを入手
13.62
8.10%
1.02
アフターアワーズ：
13.62
前日終値:
$12.60
開ける：
$13.6
24時間の取引高:
31,405
Relative Volume:
1.76
時価総額：
$961.92M
収益：
$376.88M
当期純損益:
$2.52M
株価収益率:
449.50
EPS:
0.0303
ネットキャッシュフロー:
$49.32M
1週間 パフォーマンス:
+8.10%
1か月 パフォーマンス:
-18.35%
6か月 パフォーマンス:
-23.27%
1年 パフォーマンス:
+31.21%
1日の値動き範囲:
$13.41
$13.72
1週間の範囲:
$12.34
$13.72
52週間の値動き範囲:
$9.5354
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
13.62 | 889.88M | 376.88M | 2.52M | 49.32M | 0.0303 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-09 | 開始されました | Jefferies | Buy |
Pharming Group Nv Adr (PHAR) 最新ニュース
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com India
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Large Decline in Short Interest - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Pharming Group N.V. Investigated by the Portnoy Law Firm - GlobeNewswire
Pharming (NASDAQ: PHAR) updates 20-F with corrected CEO/CFO certifications - Stock Titan
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 33.9% in March - MarketBeat
Pharming Group (NASDAQ:PHAR) Given Buy Rating at HC Wainwright - defenseworld.net
HC Wainwright Estimates Pharming Group Q3 Earnings - Defense World
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short Interest - MarketBeat
HC Wainwright Predicts Pharming Group Q1 Earnings - MarketBeat
A2QLQY Stock Price and Chart — LS:A2QLQY - TradingView
Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance - Investing.com
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Finviz
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Drop in Short Interest - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V.PHAR - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - GlobeNewswire Inc.
FY2025 EPS Estimates for Pharming Group Increased by Analyst - Defense World
Pharming shares surge as 2026 guidance tops analyst expectations - Investing.com
Pharming Group stock tumbles after FDA issues Complete Response Letter - Investing.com
Pharming Group (NASDAQ:PHAR) Sets New 1-Year HighTime to Buy? - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group stock hits 52-week high at 18.6 USD - Investing.com
Pharming Group Nv Adr (PHAR) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):